Metformin and the TAME Frame
This article is a placeholder. Only its topic and title are committed at this stage; the substantive body will be drafted in a future cycle of the engine.
The diabetes drug whose epidemiological signal in non-diabetics inspired the Targeting Aging with Metformin (TAME) trial framework. Distinguishes the “diabetes-prevention” evidence from the “aging-modulation” hypothesis; names the antioxidant-blunting concern in athletic populations (Konopka et al.) as a real trade-off rather than a fatal objection.